FIELD: medicine, pharmaceutics.
SUBSTANCE: invention concerns biotechnology. There is described a method for preparing a high-concentration liquid composition containing Mab C225 (cetuximab) or Mab h425 (EMD72000), by ultrafiltration, differing by the fact that protein is concentrated under pressure control with using polyester sulfonic ultrafiltration membrane with a severance within 5-500 kDa; and this cleaning results in the fact that the high-concentration liquid composition contains Mab C225 (cetuximab) or Mab h425 (EMD72000) in amount 50-180 mg/ml. There is presented the high-concentration liquid composition for preparing a drug for treatment and/or prevention of tumours and/or the tumour metastases containing 50-180 mg/ml Mab C225 (cetuximab) or Mab h425 (EMD72000) and an aqueous solution and application of said composition.
EFFECT: invention allows preparing stable high-concentration liquid compositions.
8 cl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SOLID FORMS OF ANTI- EGFR ANTIBODIES | 2004 |
|
RU2397755C2 |
| COMBINED THERAPY USING INHIBITORS OF TYROSINE KINASE RECEPTORS AND INHIBITORS OF ANGIOGENESIS | 2001 |
|
RU2292904C2 |
| PHARMACEUTICAL COMPOSITIONS AIMED AT Erb-B1 RECEPTORS | 2003 |
|
RU2354402C2 |
| HUMAN ANTIBODIES TO RECEPTOR OF EPIDERMAL GROWTH FACTOR | 2005 |
|
RU2402569C2 |
| PHARMACEUTICAL PREPARATION CONTAINING EGF RECEPTOR ANTIBODY | 2004 |
|
RU2381036C2 |
| CANCER TREATMENT USING ANTI-NKG2A AGENTS | 2015 |
|
RU2721271C2 |
| COMPOSITIONS OF RECOMBINANT ANTIBODIES FROM EPIDERMAL GROWTH FACTOR RECEPTOR | 2009 |
|
RU2540146C2 |
| COMBINED THERAPY BY USING ANTIANGIOGENIC AGENTS AND TNF-ALPHA | 2002 |
|
RU2316337C2 |
| PHARMACEUTICAL COMBINATIONS | 2017 |
|
RU2759669C2 |
| METHOD OF TREATING CANCER CARRYING EGFR MUTATIONS | 2007 |
|
RU2492864C2 |
